Nasdaq · CIK 0001880438
ANTX AN2 Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 26 d ago. Close $4.40 on Oct 9, 2026, +327% from the 52-week low and -30% from the high.
Last 90 days
Net insider value
-$94k
more sold than bought
Buys
1
$12k by 1 insider
Sells
3
$106k by 2 insiders
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
ANTXOct 9, 2026 · close 4.40
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at AN2 Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 3Weak | Robin Shane Readnour director sell | $6,675 1,108 shares | -0% | +456% from low-9% from high | |
| 13Weak | Robin Shane Readnour director sell | $97k 16,119 shares | -3% | +478% from low-5% from high | |
| 23Weak | Sarah Joanne Williams Principal Accounting Officer sell | $1,504 272 shares | -0% | +432% from low-13% from high | |
| 21Weak | Margaret M FitzPatrick director buy | $12k 2,098 shares | +24% | +432% from low-13% from high | |
| 23Weak | Stephen David Prior Chief Strategy Officer sell | $872 765 shares | -1% | +14% from low-32% from high | |
| 23Weak | Joshua M Eizen See Remarks sell | $3,214 2,819 shares | -2% | +14% from low-32% from high | |
| 24Weak | Braden Michael Leonard owner sell | $218k 200,000 shares | -6% | +15% from low-31% from high | |
| 51Moderate | Eric Easom Chief Executive Officer buy | $11k 10,000 shares | +4% | +6% from low-37% from high | |
| 47Moderate | Braden Michael Leonard owner sell | $2.9M 2,532,000 shares | -44% | +15% from low-31% from high | |
| 39Weak | Margaret M FitzPatrick director buy | $10k 8,610 shares | - | +15% from low-31% from high | |
| 30Weak | Joshua M Eizen See Remarks sell | $13k 9,663 shares | -8% | +42% from low-15% from high | |
| 30Weak | Stephen David Prior Chief Strategy Officer sell | $2,721 2,029 shares | -6% | +42% from low-15% from high | |
| 30Weak | Sanjay Chanda Chief Development Officer sell | $3,965 2,957 shares | -9% | +42% from low-15% from high | |
| 37Weak | Lucy Day Chief Financial Officer sell | $3,965 2,957 shares | -8% | +42% from low-15% from high | |
| 40Moderate | Robin Shane Readnour director buy | $87k 60,000 shares | +11% | - | |
| 35Weak | Joseph S Zakrzewski director buy | $2,800 2,000 shares | +2% | - | |
| 48Moderate | Robin Shane Readnour director buy | $106k 75,000 shares | +15% | - | |
| 48Moderate | Robin Shane Readnour director buy | $213k 200,000 shares | +41% | - | |
| 41Moderate | Joseph S Zakrzewski director buy | $25k 25,000 shares | +25% | - | |
| 47Moderate | Eric Easom Chief Executive Officer buy | $50k 50,000 shares | +5% | - |
Transactions
The last 78 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Cameron C. Trenor III Chief Medical Officer | AGrant or award Common Stock | +116,667 | $0.00 | $0 | 116,667 | 26 d ago |
| Sep 15, 2026 | Cameron C. Trenor III Chief Medical Officer | AGrant or award Stock Option (right to by)derivative | +233,333 | $0.00 | $0 | 233,333 | 26 d ago |
| Sep 9, 2026 | Robin Shane Readnour director | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -523 | $6.02 | $3,151 | 557,467 | 31 d ago |
| Sep 9, 2026 | Robin Shane Readnour director | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -585 | $6.02 | $3,524 | 624,765 | 31 d ago |
| Sep 3, 2026 | Robin Shane Readnour director | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -2,877 | $6.07 | $17k | 562,715 | 34 d ago |
| Sep 3, 2026 | Robin Shane Readnour director | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -3,223 | $6.07 | $20k | 630,644 | 34 d ago |
| Sep 8, 2026 | Robin Shane Readnour director | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -4,725 | $6.02 | $28k | 557,990 | 34 d ago |
| Sep 8, 2026 | Robin Shane Readnour director | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -5,294 | $6.02 | $32k | 625,350 | 34 d ago |
| Sep 1, 2026 | Sarah Joanne Williams Principal Accounting Officer | SOpen-market sale Common Stock | -272 | $5.53 | $1,504 | 66,311 | 38 d ago |
| Sep 1, 2026 | Margaret M FitzPatrick director | POpen-market purchase Common Stock | +2,098 | $5.53 | $12k | 10,708 | 40 d ago |
| Nov 4, 2025 | Stephen David Prior Chief Strategy Officer | SOpen-market sale Common Stock | -765 | $1.14 | $872 | 65,548 | Nov 6, 2025 |
| Nov 4, 2025 | Joshua M Eizen See Remarks | SOpen-market sale Common Stock | -2,819 | $1.14 | $3,214 | 177,353 | Nov 6, 2025 |
| Oct 10, 2025 | Patricia A. Martin director | AGrant or award Common Stock | +3,274 | $0.00 | $0 | 13,255 | Oct 14, 2025 |
| Oct 10, 2025 | Gilbert Lynn Marks director | AGrant or award Common Stock | +10,367 | $0.00 | $0 | 63,749 | Oct 14, 2025 |
| Oct 10, 2025 | Kabeer Aziz director | AGrant or award Common Stock | +10,367 | $0.00 | $0 | 40,919 | Oct 14, 2025 |
| Jul 10, 2025 | Patricia A. Martin director | AGrant or award Common Stock | +3,750 | $0.00 | $0 | 9,981 | Jul 11, 2025 |
| Jul 10, 2025 | Gilbert Lynn Marks director | AGrant or award Common Stock | +11,875 | $0.00 | $0 | 53,382 | Jul 11, 2025 |
| Jul 10, 2025 | Kabeer Aziz director | AGrant or award Common Stock | +11,875 | $0.00 | $0 | 30,552 | Jul 11, 2025 |
| May 28, 2025 | Braden Michael Leonard owner | SOpen-market sale Common Stockindirect: Holding of BML Investment Partners, L.P. | -200,000 | $1.09 | $218k | 3,017,432 | Jun 16, 2025 |
| Jun 2, 2025 | Eric Easom Chief Executive Officer | POpen-market purchase Common Stock | +10,000 | $1.07 | $11k | 256,380 | Jun 3, 2025 |
| May 28, 2025 | Braden Michael Leonard owner | SOpen-market sale Common Stockindirect: Holding of BML Investment Partners, L.P. | -2,000,000 | $1.16 | $2.3M | 3,749,432 | May 30, 2025 |
| May 28, 2025 | Braden Michael Leonard owner | SOpen-market sale Common Stockindirect: Holding of BML Investment Partners, L.P. | -100,000 | $1.16 | $116k | 3,649,432 | May 30, 2025 |
| May 30, 2025 | Braden Michael Leonard owner | SOpen-market sale Common Stockindirect: Holding of BML Investment Partners, L.P. | -425,000 | $1.01 | $429k | 3,224,432 | May 30, 2025 |
| May 30, 2025 | Braden Michael Leonard owner | SOpen-market sale Common Stockindirect: Holding of BML Investment Partners, L.P. | -7,000 | $1.03 | $7,227 | 3,217,432 | May 30, 2025 |
| May 28, 2025 | Margaret M FitzPatrick director | POpen-market purchase Common Stock | +8,610 | $1.18 | $10k | 8,610 | May 29, 2025 |
| May 22, 2025 | Kabeer Aziz director | AGrant or award Stock Optin (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| May 22, 2025 | Robin Shane Readnour director | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| May 22, 2025 | Patricia A. Martin director | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| May 22, 2025 | Margaret M FitzPatrick director | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| May 22, 2025 | Joseph S Zakrzewski director | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| May 22, 2025 | Melvin K Spigelman director | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| May 22, 2025 | Stephanie Wong director | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| May 22, 2025 | Gilbert Lynn Marks director | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| Apr 10, 2025 | Gilbert Lynn Marks director | AGrant or award Common Stock | +9,705 | $0.00 | $0 | 41,507 | Apr 11, 2025 |
| Apr 10, 2025 | Patricia A. Martin director | AGrant or award Common Stock | +3,065 | $0.00 | $0 | 6,231 | Apr 11, 2025 |
| Apr 10, 2025 | Kabeer Aziz director | AGrant or award Common Stock | +9,705 | $0.00 | $0 | 18,677 | Apr 11, 2025 |
| Apr 10, 2025 | Joseph S Zakrzewski director | AGrant or award Common Stock | +10,523 | $0.00 | $0 | 145,538 | Apr 11, 2025 |
| Feb 26, 2025 | Sanjay Chanda Chief Development Officer | AGrant or award Common Stock | +50,250 | $0.00 | $0 | 80,074 | Feb 28, 2025 |
| Feb 26, 2025 | Lucy Day Chief Financial Officer | AGrant or award Common Stock | +46,500 | $0.00 | $0 | 79,170 | Feb 28, 2025 |
| Feb 26, 2025 | Eric Easom Chief Executive Officer | AGrant or award Common Stock | +145,250 | $0.00 | $0 | 246,380 | Feb 28, 2025 |
| Feb 26, 2025 | Joshua M Eizen See Remarks | AGrant or award Common Stock | +58,500 | $0.00 | $0 | 175,172 | Feb 28, 2025 |
| Feb 26, 2025 | Stephen David Prior Chief Strategy Officer | AGrant or award Common Stock | +28,000 | $0.00 | $0 | 61,313 | Feb 28, 2025 |
| Feb 26, 2025 | Joshua M Eizen See Remarks | AGrant or award Stock Option (right to buy)derivative | +117,000 | $0.00 | $0 | 117,000 | Feb 28, 2025 |
| Feb 26, 2025 | Stephen David Prior Chief Strategy Officer | AGrant or award Stock Option (right to buy)derivative | +56,000 | $0.00 | $0 | 56,000 | Feb 28, 2025 |
| Feb 26, 2025 | Lucy Day Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | -93,000 | $0.00 | $0 | 93,000 | Feb 28, 2025 |
| Feb 26, 2025 | Sanjay Chanda Chief Development Officer | AGrant or award Stock Option (right to buy)derivative | +100,500 | $0.00 | $0 | 100,500 | Feb 28, 2025 |
| Feb 26, 2025 | Eric Easom Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +290,500 | $0.00 | $0 | 290,500 | Feb 28, 2025 |
| Jan 3, 2025 | Joshua M Eizen See Remarks | SOpen-market sale Common Stock | -9,663 | $1.34 | $13k | 116,672 | Jan 7, 2025 |
| Jan 3, 2025 | Stephen David Prior Chief Strategy Officer | SOpen-market sale Common Stock | -2,029 | $1.34 | $2,721 | 33,313 | Jan 7, 2025 |
| Jan 3, 2025 | Sanjay Chanda Chief Development Officer | SOpen-market sale Common Stock | -2,957 | $1.34 | $3,965 | 29,824 | Jan 7, 2025 |
| Jan 3, 2025 | Lucy Day Chief Financial Officer | SOpen-market sale Common Stock | -2,957 | $1.34 | $3,965 | 32,670 | Jan 7, 2025 |
| Dec 19, 2024 | Robin Shane Readnour director | AGrant or award Common Stock | +9,077 | $0.00 | $0 | 9,077 | Dec 23, 2024 |
| Dec 19, 2024 | Joseph S Zakrzewski director | AGrant or award Common Stock | +9,816 | $0.00 | $0 | 135,015 | Dec 23, 2024 |
| Dec 19, 2024 | Gilbert Lynn Marks director | AGrant or award Common Stock | +8,972 | $0.00 | $0 | 31,802 | Dec 23, 2024 |
| Dec 19, 2024 | Kabeer Aziz director | AGrant or award Common Stock | +8,972 | $0.00 | $0 | 8,972 | Dec 23, 2024 |
| Dec 19, 2024 | Patricia A. Martin director | AGrant or award Common Stock | +3,166 | $0.00 | $0 | 3,166 | Dec 23, 2024 |
| Dec 6, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +12,711 | $1.45 | $18k | 564,999 | Dec 10, 2024 |
| Dec 6, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +6,517 | $1.45 | $9,427 | 629,090 | Dec 10, 2024 |
| Dec 9, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +12,289 | $1.43 | $18k | 577,288 | Dec 10, 2024 |
| Dec 9, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +18,483 | $1.43 | $26k | 647,573 | Dec 10, 2024 |
| Dec 10, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +5,000 | $1.49 | $7,462 | 582,288 | Dec 10, 2024 |
| Dec 10, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +5,000 | $1.49 | $7,468 | 652,573 | Dec 10, 2024 |
| Nov 27, 2024 | Joseph S Zakrzewski director | POpen-market purchase Common Stock | +2,000 | $1.40 | $2,800 | 125,199 | Nov 27, 2024 |
| Nov 26, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +12,500 | $1.39 | $17k | 527,288 | Nov 27, 2024 |
| Nov 26, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +12,500 | $1.39 | $17k | 597,573 | Nov 27, 2024 |
| Nov 27, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $1.42 | $35k | 552,288 | Nov 27, 2024 |
| Nov 27, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $1.42 | $35k | 622,573 | Nov 27, 2024 |
| Nov 19, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +75,000 | $1.03 | $78k | 560,073 | Nov 21, 2024 |
| Nov 19, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +75,000 | $1.04 | $78k | 489,788 | Nov 21, 2024 |
| Nov 20, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $1.16 | $29k | 585,073 | Nov 21, 2024 |
| Nov 20, 2024 | Robin Shane Readnour director | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $1.15 | $29k | 514,788 | Nov 21, 2024 |
| Nov 18, 2024 | Joseph S Zakrzewski director | POpen-market purchase Common Stock | +20,000 | $1.00 | $20k | 118,199 | Nov 20, 2024 |
| Nov 19, 2024 | Joseph S Zakrzewski director | POpen-market purchase Common Stock | +5,000 | $1.01 | $5,050 | 123,199 | Nov 20, 2024 |
| Nov 18, 2024 | Eric Easom Chief Executive Officer | POpen-market purchase Common Stockindirect: See Footnote | +50,000 | $1.00 | $50k | 1,065,766 | Nov 18, 2024 |
| Nov 4, 2024 | Joshua M Eizen See Remarks | AGrant or award Common Stock | +31,500 | $0.00 | $0 | 126,335 | Nov 5, 2024 |
| Nov 4, 2024 | Stephen David Prior Chief Strategy Officer | AGrant or award Common Stock | +10,125 | $0.00 | $0 | 35,342 | Nov 5, 2024 |
| Nov 4, 2024 | Joshua M Eizen See Remarks | AGrant or award Stock Option (right to buy)derivative | +63,000 | $0.00 | $0 | 63,000 | Nov 5, 2024 |
| Nov 4, 2024 | Stephen David Prior Chief Strategy Officer | AGrant or award Stock Option (right to buy)derivative | +20,250 | $0.00 | $0 | 20,250 | Nov 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Kabeer Azizdirector
- Sanjay ChandaChief Development Officer
- Lucy DayChief Financial Officer
- Eric EasomChief Executive Officer
- Joshua M EizenSee Remarks
- Margaret M FitzPatrickdirector
- Braden Michael Leonardowner
- Gilbert Lynn Marksdirector
- Patricia A. Martindirector
- Stephen David PriorChief Strategy Officer
- Robin Shane Readnourdirector
- Melvin K Spigelmandirector
- Cameron C. Trenor IIIChief Medical Officer
- Sarah Joanne WilliamsPrincipal Accounting Officer
- Stephanie Wongdirector
- Joseph S Zakrzewskidirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.